Redox Regulation of Interleukin-4 Signaling

被引:85
|
作者
Sharma, Pankaj [1 ]
Chakraborty, Rikhia [1 ,2 ]
Wang, Lu [3 ]
Min, Booki [3 ]
Tremblay, Michel L. [5 ]
Kawahara, Tsukasa [4 ]
Lambeth, J. David [4 ]
Haque, S. Jaharul [1 ]
机构
[1] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA
[2] Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA
[3] Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA
[4] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[5] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada
基金
美国国家卫生研究院;
关键词
D O I
10.1016/j.immuni.2008.07.019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The physiologic control of cytokine receptor activation is primarily mediated by reciprocal activation of receptor-associated protein tyrosine kinases and protein tyrosine phosphatases (PTPs). Here, we show that immediately after ligand-dependent activation, interleukin (IL)-4 receptor generated reactive oxygen species (ROS) via phosphatidylinositol 3-kinase-dependent activation of NAD(P)H oxidase (NOX)1 and NOX5L. ROS, in turn, promoted IL-4 receptor activation by oxidatively inactivating PTP1 B that physically associated with and deactivated IL-4 receptor. However, ROS were not required for the initiation of IL-4 receptor activation. ROS generated by other cytokine receptors, including those for erythropoietin, tumor necrosis factor-alpha, or IL-3, also promoted IL-4 signaling. These data indicate that inactivation of receptor-associated PTP activity by cytokine-generated ROS is a physiologic mechanism for the amplification of cytokine receptor activation in both cis and trans, revealing a role for ROS in cytokine crosstalk.
引用
收藏
页码:551 / 564
页数:14
相关论文
共 50 条
  • [41] Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond
    Danielle Karo-Atar
    Almog Bitton
    Itai Benhar
    Ariel Munitz
    [J]. BioDrugs, 2018, 32 : 201 - 220
  • [42] Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond
    Karo-Atar, Danielle
    Bitton, Almog
    Benhar, Itai
    Munitz, Ariel
    [J]. BIODRUGS, 2018, 32 (03) : 201 - 220
  • [43] HUMAN INTERLEUKIN-4
    BANCHEREAU, J
    BRIERE, F
    GALIZZI, JP
    MIOSSEC, P
    ROUSSET, F
    [J]. JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1994, 9 (01): : 43 - 53
  • [44] WHICH INTERLEUKIN-4
    NEWMARK, P
    [J]. NATURE, 1986, 319 (6055) : 620 - 620
  • [45] Interleukin-4 and listeriosis
    Kaufmann, SHE
    Emoto, M
    Szalay, G
    Barsig, J
    Flesch, IEA
    [J]. IMMUNOLOGICAL REVIEWS, 1997, 158 : 95 - 105
  • [46] HUMAN INTERLEUKIN-4
    BANCHEREAU, J
    DEFRANCE, T
    GALIZZI, JP
    MIOSSEC, P
    ROUSSET, F
    [J]. BULLETIN DU CANCER, 1991, 78 (03) : 299 - 306
  • [47] History of interleukin-4
    Paul, William E.
    [J]. CYTOKINE, 2015, 75 (01) : 3 - 7
  • [48] Regulation of CD31 expression and interleukin-4 production by human cord blood CD4+ T cells with interleukin-4 and interleukin-7
    Katamura, K
    Fukui, T
    Kiyomasu, T
    Ohmura, K
    Iio, J
    Ueno, H
    [J]. PEDIATRICS INTERNATIONAL, 2000, 42 (02) : 126 - 133
  • [49] RECOMBINANT INTERLEUKIN-4
    NEILAN, BA
    WIDMER, MB
    GRABSTEIN, KH
    [J]. EXPERIMENTAL HEMATOLOGY, 1988, 16 (06) : 415 - 415
  • [50] Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases
    W Klein
    A Tromm
    T Griga
    H Fricke
    C Folwaczny
    M Hocke
    K Eitner
    M Marx
    N Duerig
    JT Epplen
    [J]. Genes & Immunity, 2001, 2 : 287 - 289